Funding for this research was provided by:
Georgia Clinical and Translational Science Alliance (TL1TR002382 and UL1TR002378)
National Aeronautics and Space Administration (NNX16AT06G)
Received: 2 March 2020
Revised: 24 December 2020
Accepted: 11 January 2021
First Online: 12 February 2021
Ethics approval and consent to participate
: This study was approved by both the NASA and Emory University IRBs.
: Not applicable.
: BAM is an employee of Alcyone Therapeutics and has served as a consultant to Roche, Genentech, Voyager Therapeutics, Praxis Medicines, InviCRO, Biogen, Voyager Therapeutics, Behavior Imaging, Medtrad Biosystems, Neurosyntek, and Cerebral Therapeutics. The authors otherwise declare that they have no competing interests.